/
Oncology
Non-Small Cell Lung Cancer (NSCLC)
29
Pipeline Programs↗
42
Active Trials↗
25
Companies Involved↗
Non-small Cell Lung Cancer (NSCLC) is an emerging landscape with 29 programs across 25 companies. The most active players are Servier Bio-Innovation LLC, Revolution Medicines, AstraZeneca. 2 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical17
Phase 13
Phase 27
Approved
No programs
Analysis
Modality Breakdown
83%
Small molecule
20 of 24 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 24 classified programs, each share of the total. Modality classified for 86% of 29 pipeline programs.
Analysis
Trial Status
52
clinical trials
Recruiting21 · 40%
Active, not recruiting11 · 21%
Not yet recruiting9 · 17%
Completed8 · 15%
Suspended1 · 2%
Enrolling by invitation1 · 2%
Other1 · 2%
Clinical Trials
Trial Activity
52 trials
Study of the Immunogenicity of the MUC1 Peptide - Poly-ICLC (Polyinosinic-polycytidylic Acid Stabilized With Polylysine and Carboxymethylcellulose) OR HILTONOL™ Adjuvant Vaccine in Patients With Localized and Locally Advanced Non-Small Cell Lung Cancer
Recruiting·—·Preclinical·NCT01720836·30 enrolled
Page 1 of 4
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)